ENTRY       D11529                      Drug
NAME        Trastuzumab deruxtecan (USAN/INN);
            Trastuzumab deruxtecan (genetical recombination) (JAN);
            Fam-trastuzumab deruxtecan-nxki;
            Enhertu (TN)
PRODUCT     ENHERTU (Daiichi Sankyo)
FORMULA     C6460H9972N1724O2014S44. (C52H57FN9O13)8
EXACT_MASS  153607.1079
MOL_WEIGHT  153701.9811
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FD04
            Product: D11529<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Breast cancer (HER2 positive) [DS:H00031]
  TYPE      Antibody-drug conjugate
TARGET      ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
            TOP1 [HSA:7150] [KO:K03163]
  PATHWAY   hsa01521(2064)  EGFR tyrosine kinase inhibitor resistance
            hsa04012(2064)  ErbB signaling pathway
            hsa05200(2064)  Pathways in cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD04 Trastuzumab deruxtecan
                  D11529  Trastuzumab deruxtecan (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Fam-Trastuzumab Deruxtecan
                D11529  Trastuzumab deruxtecan (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11529  Trastuzumab deruxtecan (USAN/INN); Trastuzumab deruxtecan (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D11529  Trastuzumab deruxtecan
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D11529  Trastuzumab deruxtecan
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
                 D11529  Trastuzumab deruxtecan (USAN/INN) &lt;JP/US&gt;
             Enzymes
              Isomerases (EC5)
               DNA topoisomerase
                TOP1
                 D11529  Trastuzumab deruxtecan (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11529
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11529
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11529
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11529
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11529
DBLINKS     CAS: 1826843-81-5
            PubChem: 384585505
///
